J.M. Sánchez-Torres

Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation

R. Porta, J.M. Sánchez-Torres, Luis Paz‐Ares et al. · European Respiratory Journal · 2010 · 316 citations · Full text

Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients

Jacobo Rogado, J.M. Sánchez-Torres, Nuria Romero-Laorden et al. · European Journal of Cancer · 2019 · 252 citations

Cancer Immunosurveillance, Autoimmune Disease, Medicine +13

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 111 citations · Full text

Advanced Nsclc, Booster Trial, Novel Therapy +8

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

J. Zugazagoitia, Inmaculada Ramos, José Trigo et al. · Annals of Oncology · 2018 · 83 citations · Full text

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Giorgio V. Scagliotti, Igor Bondarenko, Fiona Blackhall et al. · Annals of Oncology · 2014 · 64 citations · Full text

Erlotinib Versus Erlotinib, Medicine, Pathology +7